Founded in 2023, ALLEGRIA Therapeutics develops therapies targeting mast cells to treat allergies and associated inflammatory diseases. The USD 5.1 million seed extension will advance its lead programme towards designating a first clinical candidate.
- Announced on
- Round
- Seed
- Amount
- USD 5.1 M
- Location
- canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- ALK Abelló lead
- HighLight Capital (HLC)
- Lichtsteiner Foundation
- Forty51 Ventures
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic